Virtus ETF Advisers’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Virtus ETF Advisers’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-25,259	Closed	-$612K	–	182
2017 Q1	$612K	Buy	25,259 +2,429	+11%	+$60.8K	0.11%	92
2016 Q4	$733K	Buy	22,830 +10,109	+79%	+$431K	0.22%	84
2016 Q3	$636K	Buy	12,721 +1,603	+14%	+$66.5K	0.31%	60
2016 Q2	$472K	Buy	11,118 +7,105	+177%	+$387K	0.35%	63
2016 Q1	$264K	Sell	4,013 -254	-6%	-$13.3K	0.36%	62
2015 Q4	$265K	Buy	+4,267	New	+$300K	0.73%	58

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Virtus ETF Advisers's MACK Position: Q2 2017 in Review

Virtus ETF Advisers sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 25,259 shares — an estimated $612K sold.

Virtus ETF Advisers first reported a position in MACK in Q4 2015 and held it in 6 quarters. The position peaked at $733K in Q4 2016. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

Virtus ETF Advisers reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Virtus ETF Advisers sold 25,259 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $612K.
Virtus ETF Advisers first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
Virtus ETF Advisers's Merrimack Pharmaceuticals, Inc. position peaked at $733K in Q4 2016.
119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on Virtus ETF Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.